These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 36618947)
1. Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy. Li C; Zhou Z; Ren C; Deng Y; Peng F; Wang Q; Zhang H; Jiang Y Front Pharmacol; 2022; 13():1007723. PubMed ID: 36618947 [TBL] [Abstract][Full Text] [Related]
2. Triplex-forming oligonucleotides as modulators of gene expression. Guntaka RV; Varma BR; Weber KT Int J Biochem Cell Biol; 2003 Jan; 35(1):22-31. PubMed ID: 12467644 [TBL] [Abstract][Full Text] [Related]
3. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells. Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of transcription and antiproliferative effects in a cancer cell line using antigene oligonucleotides containing artificial nucleoside analogues. Wang L; Notomi R; Sasaki S; Taniguchi Y RSC Med Chem; 2023 Aug; 14(8):1482-1491. PubMed ID: 37593572 [TBL] [Abstract][Full Text] [Related]
5. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Hélène C Anticancer Drug Des; 1991 Dec; 6(6):569-84. PubMed ID: 1772570 [TBL] [Abstract][Full Text] [Related]
6. Triplex-forming oligonucleotides as potential tools for modulation of gene expression. Rogers FA; Lloyd JA; Glazer PM Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):319-26. PubMed ID: 16101484 [TBL] [Abstract][Full Text] [Related]
15. Transplatin-conjugated triplex-forming oligonucleotides form adducts with both strands of DNA. Campbell MA; Miller PS Bioconjug Chem; 2009 Dec; 20(12):2222-30. PubMed ID: 19950917 [TBL] [Abstract][Full Text] [Related]
16. Binding of triple helix forming oligonucleotides to sites in gene promoters. Durland RH; Kessler DJ; Gunnell S; Duvic M; Pettitt BM; Hogan ME Biochemistry; 1991 Sep; 30(38):9246-55. PubMed ID: 1892832 [TBL] [Abstract][Full Text] [Related]
17. Purine- and pyrimidine-triple-helix-forming oligonucleotides recognize qualitatively different target sites at the ribosomal DNA locus. Maldonado R; Filarsky M; Grummt I; Längst G RNA; 2018 Mar; 24(3):371-380. PubMed ID: 29222118 [TBL] [Abstract][Full Text] [Related]
18. The cooperative interaction of triplex forming oligonucleotides on DNA-triplex formation at electrode surface: Molecular dynamics studies and experimental evidences. Petralia S; Forte G; Zimbone M; Conoci S Colloids Surf B Biointerfaces; 2020 Mar; 187():110648. PubMed ID: 31767411 [TBL] [Abstract][Full Text] [Related]
19. Kinetic study of the binding of triplex-forming oligonucleotides containing partial cationic modifications to double-stranded DNA. Hari Y; Ijitsu S; Akabane-Nakata M; Yoshida T; Obika S Bioorg Med Chem Lett; 2014 Jul; 24(14):3046-9. PubMed ID: 24865415 [TBL] [Abstract][Full Text] [Related]
20. Targeting DNA with "light-up" pyrimidine triple-helical forming oligonucleotides conjugated to stabilizing fluorophores (LU-TFOs). Renard BL; Lartia R; Asseline U Org Biomol Chem; 2008 Dec; 6(23):4413-25. PubMed ID: 19005602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]